Evidence map›Paper›PMID 39909902›Full record

ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Challenges and advances in ocular mucous membrane pemphigoid (OMMP); from pathogenesis to treatment strategies.

Hamidreza Ghanbari, Masoud Rahimi, Ali Momeni, Mehdi Aminizade, Zohreh Nozarian, Amirhossein Moghtader, Daniel E Rubinstein, Sayan Basu, Virender S Sangwan, Ali R Djalilian and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hamidreza GhanbariEye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran.
Masoud RahimiEye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran.
Ali MomeniEye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran.
Mehdi AminizadeEye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran.
Zohreh NozarianEye Research Center, Farabi Eye Hospital, Qazvin Sq, Tehran, Iran.
Amirhossein MoghtaderDepartment of Ophthalmology and Visual Science, Cornea Service, Eye and Ear Infirmary, University of IL, University of Illinois at Chicago, Chicago, IL, USA.
Daniel E RubinsteinUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sayan BasuDepartment of Ophthalmology and Visual Science, Cornea Service, Eye and Ear Infirmary, University of IL, University of Illinois at Chicago, Chicago, IL, USA.
Virender S SangwanStem Cell, Dr. Shroff's Charity Eye Hospital, Delhi, Delhi, India.
Ali R DjalilianDepartment of Ophthalmology and Visual Science, Cornea Service, Eye and Ear Infirmary, University of IL, University of Illinois at Chicago, Chicago, IL, USA.
Mohammad SoleimaniUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA. msolei@unc.edu.ORCID http://orcid.org/0000-0002-6546-3546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMucous membrane pemphigoid (MMP) is a systemic autoimmune condition characterized by blistering and cicatrization, predominantly affecting mucous membranes, including those lining the esophagus, oropharynx, nasal cavity, trachea, conjunctiva, and genitalia. Ocular mucous membrane pemphigoid (OMMP) is observed in approximately 70% of MMP cases. This study aims to review the pathophysiology, clinical manifestations, diagnosis, treatment, and complications of OMMP.

methodsA literature search was conducted using MEDLINE and EMBASE databases.

resultsOMMP is characterized by the deposition of autoantibodies along the basement membrane zone of mucous membranes, particularly affecting the conjunctival epithelium. OMMP manifests as chronic ocular discomfort, inflammation, conjunctival scarring, eyelid abnormalities, and visual impairment. Given the extensive range of similar conditions, including drug-induced pseudo-pemphigoid and paraneoplastic conjunctival cicatrization, challenges in differential diagnosis may arise. The clinical diagnosis of OMMP is supported by confirmatory biopsy with histopathology and immunofluorescence studies. The mainstay of management includes systemic immunomodulatory medications and anti-inflammatory agents, tailored to disease severity. Surgical interventions may be necessary, although caution is warranted due to the risk of exacerbating OMMP. Prompt diagnosis and treatment are essential to halt disease progression and prevent vision loss. Complications of OMMP include corneal disorders, lid disorders, and vision disturbances. A comprehensive understanding of OMMP aids in timely intervention and improved patient outcomes.

conclusionOMMP is a bilateral, chronic, progressive, relapsing-remitting condition. Early diagnosis and treatment of OMMP are necessary to prevent disease progression. The management of OMMP varies according to the severity of the disease, but often involves both medical control of the underlying inflammatory process and subsequent surgical correction of residual anatomical changes.

Indexed as

ConjunctivaDisease ManagementPemphigoid, Benign Mucous MembraneDiagnosis, DifferentialHumansAutoimmune disorderImmunomodulatory therapyMMPOcular mucous membrane pemphigoidPemphigoid

Identifiers

PMID39909902

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.